Explore this article's sources with AI
Follow PeptideMethods on Google
Lower Dose CagriSema in REDEFINE 9
REDEFINE 9 found that two lower CagriSema dose levels reduced average body weight more than placebo over 68 weeks in adults without diabetes.
Why we wrote this. Lower CagriSema dose levels now have placebo controlled phase 3b results, but the similar estimates require careful interpretation rather than an unsupported dose ranking.
In this article (5 sections)
The phase 3b REDEFINE 9 trial found that two lower dose levels of once weekly CagriSema produced greater average weight loss than placebo at 68 weeks. The trial randomized 309 adults without diabetes who had obesity, or overweight with an obesity related complication. CagriSema combines cagrilintide with semaglutide. This result applies to the tested combination, dose levels, population and monitored trial setting[1].
How REDEFINE 9 was designed
Investigators recruited adults at 24 sites in Canada, France, Germany, the United Kingdom and the United States. Eligibility required a body mass index of at least 30 kg/m², or at least 27 kg/m² with one or more weight related complications. People with diabetes were excluded. Mean age was 48.0 years and mean BMI was 39.1 kg/m². Women made up 77% of the randomized population[2].
Participants were allocated in a 2:1:2:1 ratio to CagriSema 1.7 mg of each component, its matched placebo, CagriSema 1.0 mg of each component, or its matched placebo. The two placebo groups were pooled for analysis. Treatment lasted 68 weeks, followed by continued nutrition and physical activity counselling through week 74. Blinding operated within each dose level[1].
The protocol used gradual escalation, but the schedule was part of a controlled research design. It is not an instruction for changing a prescription. The two primary outcomes were percentage change in body weight and the proportion losing at least 5% of baseline weight at week 68.
Both tested dose levels separated from placebo
For the trial's efficacy estimand, mean body weight changed by -20.7% with CagriSema 1.7 mg of each component, -21.0% with 1.0 mg of each component and -2.0% with pooled placebo. Estimated differences versus placebo were -18.8 percentage points for the 1.7 mg level and -19.0 percentage points for the 1.0 mg level. Both confidence intervals excluded no difference, and both comparisons had p values below 0.0001[2].
At least 5% weight loss was estimated for 95.1% of participants assigned to the 1.7 mg level and 96.3% assigned to the 1.0 mg level, compared with 33.4% for placebo. The corresponding estimated differences were 61.7 and 63.0 percentage points. These are group estimates from the prespecified analysis, not guarantees for an individual[1].
The two active arms produced similar average results, but REDEFINE 9 was designed to compare each dose level with placebo. Similar point estimates do not prove that the doses are equivalent or interchangeable. A direct noninferiority or equivalence question requires its own margin and analysis.
Completion and adverse events
Of 309 randomized participants, 291, or 94%, completed the study. At week 68, 254 participants, or 82%, remained on treatment. The difference between study completion and continued treatment matters because the efficacy estimand accounts for treatment discontinuation rather than describing only persistent users[2].
Adverse events were reported by 102 of 103 treated participants at the 1.7 mg level, 98 of 103 at the 1.0 mg level and 93 of 102 receiving placebo. Most events were mild or moderate and gastrointestinal. The indexed abstract reports no deaths. It does not provide a complete event by event table, serious event breakdown or reason specific discontinuation data[1].
High event proportions need context. They count participants with at least one event and do not show that every event was severe or caused by treatment. Conversely, a 68 week trial with about 300 people cannot exclude uncommon or delayed harms. The publisher full text was not accessible to our retrieval route, so this readout does not add safety details absent from the complete PubMed abstract.
What the trial can and cannot answer
Randomization, placebo control and blinding strengthen the comparison for the two primary outcomes. The multinational design is also broader than a single center study. Still, the population excluded diabetes, was predominantly female and had a high mean starting BMI. Results may differ in people with diabetes, lower starting BMI, different demographic representation or clinical conditions excluded by the protocol.
Every group received nutrition and physical activity counselling. The study therefore estimates the added effect of assigned treatment within that shared program, not the effect of the medicine without support. Follow up through week 74 cannot establish whether weight change persists years later or what happens after longer treatment cessation.
Novo Nordisk funded the trial. The abstract does not expose the full author conflict statement or the sponsor's detailed operational role. Sponsor funding does not erase randomization, but complete methods, analysis decisions and disclosures remain important when judging a company funded result[2].
Why this lower dose study matters
Earlier CagriSema development emphasized a higher 2.4 mg level for each component. REDEFINE 9 supplies randomized evidence that 1.7 mg and 1.0 mg levels also produced substantial average weight reductions relative to placebo in adults without diabetes. It does not establish which level should be selected for a particular person or whether one lower level has the best benefit to harm balance.
A useful next step is a direct comparison powered to distinguish dose levels, with complete tolerability, discontinuation and serious adverse event reporting. Longer follow up would clarify durability. Studies in people with diabetes and more varied baseline characteristics would show how far these findings travel beyond this trial population.
This readout should be considered alongside the broader semaglutide evidence overview. The combination result cannot be attributed to semaglutide alone, because REDEFINE 9 did not include semaglutide only or cagrilintide only arms.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
How much weight did participants lose in REDEFINE 9?
Mean weight changed by -20.7% with CagriSema 1.7 mg of each component and -21.0% with 1.0 mg of each component, compared with -2.0% for pooled placebo at week 68.
Did the trial prove the two lower doses are equivalent?
No. Each active dose was tested against placebo. Similar estimates do not establish equivalence or show which dose has the best benefit to harm balance.
Were people with diabetes included?
No. The 309 randomized adults had obesity, or overweight with a related complication, and did not have diabetes.
What were the main safety findings?
Adverse events were common in every group and were mostly mild or moderate gastrointestinal events. No deaths were reported, but the abstract does not provide the complete safety table.
Sources
- [1]PubMed record for REDEFINE 9, PMID 43033821Tier 1 · primary↩
- [2]NCBI EFetch abstract for REDEFINE 9, PMID 43033821Tier 1 · primary↩
No revisions yet. First published .